Anika Therapeutics (NSDQ:ANIK) reported its second-quarter financial results today, topping sales and earnings estimates on Wall Street.
The Bedford, Mass.-based company posted profits of $10 million, or 69¢ per share, on sales of $30.5 million for the 3 months ended June 30, for bottom-line loss of -11% on sales loss of -9% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Anika tops sales, EPS estimates with Q2 results appeared first on MassDevice.